About This Event

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), visits the Nasdaq MarketSite in Times Square to celebrate the approval and successful launch of TRYNGOLZA™ (olezarsen), their first independent medicine and first-ever treatment for adults living with familial chylomicronemia syndrome.

In honor of the occasion, Brett Monia, Ph.D., Chief Executive Officer, rings the Opening Bell.